Studies have shown that the therapeutic strategy of inhibiting BChE activity can effectively improve cognitive function in patients with Alzheimer’s disease (AD) (Macdonald et al., 2017; De Candia et al., 2023). This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.